Rohan Dharmakumar
8
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Dexrazoxane to Protect Against Hemorrhagic STEMI
Role: lead
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Role: lead
Arrhythmias in Hemorrhagic Myocardial Infarction During the Acute Post-PCI Phase
Role: lead
Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
Role: lead
Novel Imaging Biomarkers for Mechanical Complications in Acute Myocardial Infarction
Role: lead
Hemorrhagic MI Prediction Score Model
Role: lead
National Landscape of Hemorrhagic Myocardial Infarction in the United States
Role: lead
Hemorrhagic Myocardial Infarction Detection by Post-reperfusion Troponin Kinetics
Role: lead
All 8 trials loaded